Acting as a soluble circulation trap for VEGF, aflibercept binds firmly to the target, clears it from the vitreous, and therefore inhibits binding and activation of the VEGF receptors. The affinity of aflibercept to VEGF-A is considerably higher than that for monoclonal anti-VEGF antibodies. This high-affinity binding is observed in vivo as one-month intravitreal binding.
Quiz Module 9.5
To validate your answers and keep track of your progress please sign in or register a new account
1. Which anti-VEGF agent has been shown to bind to all isomers of the VEGF-A family, VEGF-B, and placental growth factor?
2. Which study demonstrated the effectiveness of aflibercept for DME?